Omics Revolution

 

 

"The Omics Revolution: Beyond Genomics"

The Oaks Resort, Port Douglas, Queensland, Australia
Sunday 8th September, 2019

This one-day satellite will focus on the key role that proteomic and other omics technologies will play in the development of personalised/precision medicine. The meeting will be held immediately prior to the 13th Australian Peptide Conference (apc2019.org). Previous successful meetings in this series were held in conjunction with the 2013 APC meeting in Penang, the 2015 meeting in Kingscliff, and the 2017 meeting in Noosa. HUPO 2019 (hupo2019.org) will be held in Adelaide the following week (15th – 18th September 2019).

This satellite is free for all registrants of the 13th Australian Peptide Conference, but you will need to register. For those only attending the satellite meeting, registration will be $175. This will include morning coffee, lunch and attendance at the opening mixer of the main meeting. A number of speaking slots are still available. Registration and abstract submission are open at apc2019.org. For further information contact ed.nice@monash.edu (mobile +61 421346716).

Sessions will cover Cancer Proteomics, Biomarkers, Diagnostics, Emerging Technologies, Biosensors and Personalised Medicine.

Current confirmed speakers include:

Professor Mibel Aguilar is a Bioanalytical and Biophysical Chemist at Monash University whose research focuses on biomembrane nanotechnology, peptidomimetic drug design and biomaterials for regenerative medicine. She completed her PhD in Chemistry at the University of Melbourne studying the metabolism and toxicity of paracetamol. She then completed a Post Doctoral position at St Vincent’s Institute for Medical Research working on developing physical models for protein analysis and purification. She then moved to Monash University where her group now focuses on peptide-based biomaterials and drug design and biomembrane nanotechnology and are developing novel compounds that allow us to exploit the potential of peptides as drugs. Their membrane nanotechnology projects involve the development of new biosensor methods for the analysis of membrane-mediated processes such as apoptosis, G protein-coupled receptor function and antimicrobial peptide function.

 

Malcolm Buckle is currently a Director of Research in the CNRS in France and is director of a fundamental biology research laboratory (LBPA) at the Ecole Normale Supérieure de Paris-Saclay in Cachan France.  Following a PhD in Solid Phase Peptide Synthesis with Roger Epton at Wolverhampton Polytechnic in the UK, he held a series of post-doctoral positions in Canada, Italy and France and finally became a senior scientist at the CNRS working at the Pasteur Institute Paris. After moving to the ENS Cachan, from 2002 to 2015 he directed a group working on the control and regulation of transcription and although his research interests have covered a fairly broad spectrum ranging from solid phase peptide synthesis through bioenergetics to the control of gene expression, he has always been struck by the necessity of developing techniques that allow time-resolved analysis of dynamic systems. This has led to the development and use of rapid high-energy UV lasers to follow the photo-reactivity of DNA involved in nucleoprotein complexes. The application of this technique (called PhAST after Photochemical Analysis of Structural Transitions) to nucleosomes in vitro has completely changed our way of thinking about how nucleosome positioning is perceived. Malcolm was an early user of emerging technologies based on Surface Plasmon Resonance (SPRi) and realised early that these techniques were severely limited by problems associated with the interface between a surface-based biosensor surface (a biochip) and macromolecules in solution. His group ‘the Dynamics of Macromolecular Complexes’ at the LBPA has developed a unique surface chemistry with a wide range of applications ranging from biosensor surfaces to nanoparticles with tremendous potential for use in diagnostic assays for example in the detection of cancer, autoimmune and neurodegenerative related diseases. Malcolm is currently involved in a maturation phase for valorisation of their chemistry and the aim at the end of 2019 is to create a start-up company. Malcolm has authored over 100 peer reviewed articles and reviews and holds three patents.

Kate S. Carroll is an Associate Professor with tenure in the Department of Chemistry at The Scripps Research Institute in Jupiter, Florida. She received her B.A. degree in Biochemistry from Mills College in 1996 and Ph.D. in Biochemistry from Stanford University in 2003. Her postdoctoral work was completed at the University of California, Berkeley, where she was a Damon Runyon-Walter Winchell Chancer Fund Fellow with Prof. Carolyn Bertozzi. She was an Assistant Professor at the University of Michigan until 2010, when she joined the Chemistry faculty at Scripps. From 2014 – 2017, Dr. Carroll was a permanent member of the Synthetic and Biological Chemistry NIH Study Section A and currently serves as an associate editor at ACS Chemical Research in Toxicology (2018 – ). She is also on the editorial board of Cell Chemistry and Biology and a member of ‘Faculty of 1000’. Dr. Carroll is the recipient of the ACS Pfizer Award in Enzyme Chemistry (2013), Camille Dreyfus Teacher-Scholar Award (2010), Scientist Development Award from American Heart Association (2008), and Special Fellow Award from the Leukemia and Lymphoma Society (2006). In 2016, Dr. Carroll was elected by her peers to serve as Vice-Chair (2018) and Chair (2020) of the Thiol-Based Redox Regulation and Signaling GRC. Professor Carroll’s research interests span the disciplines of chemistry and biology with an emphasis on studies of sulfur biochemistry pertinent to disease states. Her lab focuses on the development of novel tools to study redox modifications of cysteine thiols, profiling changes in protein oxidation associated with disease, and exploiting this information for development of diagnostic and therapeutic approaches.

Dr. Clarke received his Ph.D. in Mass Spectrometry and Analytical Chemistry from the University of Kent, United Kingdom and completed his postdoctoral fellowship training in Biomedical Mass Spectrometry at the Mayo Clinic. He was Principle Investigator at the Schering-Plough Research Institute in Kenilworth NJ, running the drug discovery metabolite identification group and worked at ActivX Biosciences as Director of Mass Spectrometry before joining Quest Diagnostics. Dr. Clarke is Vice President for Advanced Technology and Solution Development overseeing R and D developments and developing LC-MS/MS, Microsampling, Infectious Disease and Immunology assays utilized across Quest Diagnostics. His staff trains visiting scientists from other Quest Diagnostics labs in adopting new technology and assays from his R&D groups. He also oversees the running of LCMS/MS assays across multiple operations laboratories within the Quest network as well as the Technology Transfer portion of the Global Diagnostic Network. He has published extensively in top tier journals and textbooks and is an internationally recognized speaker and award winner. He holds over 50 patents.

 

Christie Hunter is the Director of Applications at SCIEX. Christie and her team are focused on developing and testing innovative MS workflows to analyse biomolecules, and work collaboratively with the instrument, chemistry and software research groups. Her primary area of focus is the application of MS based tools for the quantitative analysis of proteins and using MRM and DIA MS strategies.

Dr. Cecilia Lindskog is a group leader at Uppsala University, Uppsala, Sweden. Her research focuses on protein science and integrated omics technologies, for further understanding the biology and functions of different organs, and underlying mechanisms leading to cancer and other diseases. She has a PhD in pathology from the Faculty of Medicine, Uppsala University, and joined the Human Protein Atlas in 2006. Since 2014, Dr. Lindskog is director of the Tissue Atlas. Her team creates a world unique atlas of spatial proteomics (www.proteinatlas.org), with the aim to show the cell type-specific localization of all human proteins in normal and cancer tissues.

Jane Nielsen is a Senior Lecturer in Law at the University of Tasmania. She is Associate Head (Research) for the Law School, and a member of the University of Tasmania Social Sciences Human Research Ethics Committee. She is a member of the Centre for Law and Genetics (CLG) and an associate investigator with the Australian Centre of Excellence for Electromaterials Science. She has a longstanding research interest in the intellectual property aspects of innovation, and in other forms of regulation of emerging technologies. Jane is currently a CI on two ARC Discovery Grants, one investigating the legal issues around genomic data sharing, and the other exploring the reform of the regulatory scheme around innovative health technologies. The latter project will aim to map the regulatory environment around innovative health technologies, and assess gaps and areas of over-regulation.

Blaine R. Roberts is an Associate Professor at the Florey Institute of Neuroscience and Mental Health-University of Melbourne. He has spent his career developing and applying bioanalytical tools to understand the role of metalloenzymes in Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS). His contributions to unravelling the role of mutant Cu, Zn superoxide dismutase has contributed to the development of a clinical trial for ALS and Parkinson’s disease. And he continues to apply metalloproteomics to understand the role of essential trace elements in neurodegenerative disease. Dr. Roberts earned his B.S. in chemistry from Montana State University-Bozeman and his Ph.D. in biochemistry & biophysics at Oregon State University in 2007 under the guidance of Professor Joe Beckman. His Ph.D. studies were focused around the structural rearrangements caused by the mis-metallation of metalloenzymes and their role in neurodegenerative diseases. Following his Ph.D. he was a post-doc under the guidance of Professor Colin Masters at the Mental Health Research Institute where he worked to understand the role of amyloid beta and metals in Alzheimer’s disease brain. In 2013, Dr. Roberts became an independent lab head and obtained funding to setup the Neuroproteomics and Metalloproteomics lab at the Florey. In 2015, he joined the faculty of the Florey where he continues to define the role of metalloenzymes in biology and develop blood based biomarkers for neurodegenerative diseases. He is a member of the Society of Biological Inorganic Chemistry, the International Society for Neurochemistry, the scientific review board for Alzheimer’s Drug Discovery Foundation and an Agilent thought leader.

Tara Pukala obtained a PhD from the University of Adelaide in 2006, under the supervision of Prof John Bowie. This was followed by a postdoctoral position at the University of Cambridge, UK, working with Prof Dame Carol Robinson in the field of native mass spectrometry.

Tara returned to Australia to her current role as lecturer in the Discipline of Chemistry at the University of Adelaide in 2008. Here she leads a multidisciplinary research group focused on developing new approaches, primarily utilising mass spectrometry, to investigate the structure, function and interactions of macromolecules important in biology.

Tara is a past recipient of the Australian and New Zealand Society for Mass Spectrometry Bowie Medal, and since 2017 has had the role of Scientific Director of the Adelaide Proteomics Centre.

Dr. Toyama has 10 years of proteomics research experience. His areas of expertise also include quantitative mass spectrometry, with a particular focus on bioanalysis, metabolomics, and endocrinology. At Shimadzu, he has been involved in academic research collaborations, application development, and specification development of mass spectrometers. Dr. Toyama has a Master of Science degree in Biochemistry from the University of Cambridge, in the UK, and a PhD in Biological Sciences from the University of Tokyo, for his research on clinical proteomics.

Simone is an Associate at Davies Collison Cave in Brisbane, Australia.  She specialises in the preparation and prosecution of patent applications in the areas of pharmaceutical and medicinal chemistry, biotechnology and biochemistry.  Prior to commencing her career as a patent attorney, Simone completed her PhD at the Institute for Molecular Bioscience at The University of Queensland, Australia.  Her doctorate focused on the functional and structural characterisation of bioactive peptides in animal venoms.  Her postdoctoral research at a multinational biotechnology company involved the synthesis and functional characterisation of orally stable peptide therapeutics and resulted in several patents.  Simone also holds a Bachelor of Biotechnology (Drug Design and Development) with First Class Honours from The University of Queensland.

James Whisstock performed his PhD in bioinformatics and structural biology at the University of Cambridge.  In 1997, he moved to Australia and established his group at Monash University. James is currently an ARC Laureate Fellow, Honorary NHMRC Senior Principal Research Fellow, he is the Scientific Director of the Australian Research Council Centre of Excellence in Advanced Molecular Imaging and he is the Scientific Head of the Australian EMBL partnership.  His previous appointments include an ARC Federation Fellowship.  James was awarded the 2006 Science Ministers prize, the 2008 Health ministers prize and the 2010 Gottschalk medal. James's current research directions include understanding the structure and function of pore forming proteins in immunity and Drosophila development (e.g. Rosado et al., Science 2007. Law et al., Nature 2010). His team further investigates the proteases and their inhibitors that control blood coagulation and wound remodelling.  Over the course of his career at Monash, James has further led the development of several key technology platforms, including protein production, eResearch and protein crystallography. Most recently he led the initiative to establish Australia's first most advanced Cryo-Electron Microscopy unit.

Professor Hanmei Xu is currently director of Jiangsu Engineering Research Center of Synthetic Polypeptide Drug Discovery and Valuation. She is a member of the Chinese National Pharmacopoeia Committee and a holder of a national “Ten Thousand Talent Program” and received an award for National Innovation and Entrepreneurial Talent in 2015 Over the last decade, Professor Xu has devoted her studies to the independent design and synthesis of peptide drugs. Two of these have been approved for clinical trials in China. Her group has also discovered a number of potential biomarkers (including lncRNAs, micRNAs and proteins) for esophageal carcinoma cell carcinoma, breast cancer, head and neck squamous carcinoma by focusing on genomics and transcriptomics. She is on over 35 patents.